<?xml version="1.0" encoding="UTF-8"?>
<ref id="bib30">
 <label>30</label>
 <element-citation publication-type="journal" id="sref30">
  <person-group person-group-type="author">
   <name>
    <surname>Wedemeyer</surname>
    <given-names>H.</given-names>
   </name>
   <name>
    <surname>Port</surname>
    <given-names>K.</given-names>
   </name>
   <name>
    <surname>Deterding</surname>
    <given-names>K.</given-names>
   </name>
   <name>
    <surname>Wranke</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Kirschner</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>Bruno</surname>
    <given-names>B.</given-names>
   </name>
  </person-group>
  <article-title>PS-039 - a phase 2 dose-escalation study of lonafarnib plus ritonavir in patients with chronic hepatitis D: final results from the Lonafarnib with ritonavir in HDV-4 (LOWR HDV-4) study</article-title>
  <source>JÂ Hepatol</source>
  <volume>66</volume>
  <year>2017</year>
  <fpage>S24</fpage>
 </element-citation>
</ref>
